Gainers
- Verona Pharma (NASDAQ:VRNA) stock increased by 71.8% to $11.94 during Tuesday's pre-market session. The company's market cap stands at $720.7 million.
- Ontrak (NASDAQ:OTRK) shares increased by 48.46% to $1.01. The company's market cap stands at $26.2 million. As per the news, the Q2 earnings report came out today.
- GoodRx Holdings (NASDAQ:GDRX) shares moved upwards by 32.08% to $10.25. The company's market cap stands at $4.0 billion. As per the press release, Q2 earnings came out yesterday.
- BIMI Intl Medical (NASDAQ:BIMI) shares moved upwards by 26.38% to $0.78. The company's market cap stands at $21.9 million.
- Mersana Therapeutics (NASDAQ:MRSN) stock moved upwards by 22.66% to $6.44. The market value of their outstanding shares is at $624.6 million. As per the press release, Q2 earnings came out yesterday.
- Erytech Pharma (NASDAQ:ERYP) shares moved upwards by 15.17% to $1.29. The company's market cap stands at $40.0 million.
Losers
- Cormedix (NASDAQ:CRMD) stock declined by 58.8% to $3.1 during Tuesday's pre-market session. The market value of their outstanding shares is at $121.2 million.
- Aytu BioPharma (NASDAQ:AYTU) stock declined by 38.17% to $0.36. The company's market cap stands at $13.8 million.
- Novavax (NASDAQ:NVAX) stock declined by 31.29% to $39.34. The company's market cap stands at $3.0 billion. As per the news, the Q2 earnings report came out yesterday.
- Quanterix (NASDAQ:QTRX) stock decreased by 27.96% to $11.88. The company's market cap stands at $438.4 million. The company's, Q2 earnings came out yesterday.
- Eargo (NASDAQ:EAR) stock decreased by 19.71% to $1.1. The company's market cap stands at $43.2 million. The company's, Q2 earnings came out yesterday.
- DermTech (NASDAQ:DMTK) shares declined by 18.17% to $6.9. The company's market cap stands at $206.5 million. As per the press release, Q2 earnings came out yesterday. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Market News and Data brought to you by Benzinga APIs
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.